FDA Approves Treosulfan as Part of AML/MDS Conditioning Regimen

May Be Interested In:Breathe Easy: Simple Indoor Air Quality Hacks for Renters


The FDA approved treosulfan (Grafapex) with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in patients ages 1 year and older with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), Medexus announced on Wednesday.

“This FDA approval provides a useful option for adult and pediatric patients, with the potential to enhance overall survival [OS] while minimizing side effects,” said Filippo Milano, MD, PhD, of the Fred Hutch Cancer Center in Seattle, in the company press release.

The regimen was evaluated in MC-FludT.14/L Trial II, which compared treosulfan versus busulfan alongside fludarabine in 570 patients. Eligible patients included adults with AML or MDS, a Karnofsky performance status ≥60%, and age ≥50 years or a hematopoietic cell transplantation comorbidity index score >2.

Compared with busulfan, the hazard ratio for OS was 0.67 (95% CI 0.51-0.90) in favor of treosulfan in the randomized population, 0.73 (95% CI 0.51-1.06) in patients with AML and 0.64 (95% CI 0.40-1.02) in patients with MDS.

The most common adverse events included musculoskeletal pain, stomatitis, pyrexia, nausea, edema, infection, and vomiting. Selected grade 3 or 4 non-hematologic laboratory abnormalities were increased gamma-glutamyl transferase, bilirubin, alanine aminotransferase, aspartate aminotransferase, and creatinine.

Previously reported data from the trial showed a 2-year event-free survival rate of 64% in the treosulfan group versus 50.4% in the busulfan group (P<0.0001).

Patients who received treosulfan also had an improved 2-year OS rate (87.5% vs 69%, P=0.0082) and lower rates of transplantation-related mortality (12.1% vs 28.2%, P=0.020) and non-relapse mortality (11.4% vs 22.6%, P=0.053) compared with patients who received busulfan. The 2-year relapse rates were similar between the two groups (24.6% vs 23.3%, respectively, P=0.50).

  • Mike Bassett is a staff writer focusing on oncology and hematology. He is based in Massachusetts.

share Share facebook pinterest whatsapp x print

Similar Content

Giant Bombcast 870: Sanctuary
Giant Bombcast 870: Sanctuary
Meta Layoffs: leaked memo reveals 3,000 employees will be handed pink slips tomorrow
Meta Layoffs: Leaked memo reveals almost 4,000 employees will be handed pink slips tomorrow | Company Business News
Breathe Easy: Simple Indoor Air Quality Hacks for Renters
Breathe Easy: Simple Indoor Air Quality Hacks for Renters
‘From Ground Zero’ Review: Palestine’s Oscar Entry Compiles 22 Video Diaries From Gaza
‘From Ground Zero’ Review: Palestine’s Oscar Entry Compiles 22 Video Diaries From Gaza
Rise and shine with the seven best sunrise alarm clocks, tried and tested
Rise and shine with the seven best sunrise alarm clocks, tried and tested
Abbott’s 2024 NCAA All-Canadians: Defence
Abbott’s 2024 NCAA All-Canadians: Defence
Unscripted News: Where Reality Hits Hard | © 2025 | Daily News